AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26222998 — intervention group
Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 72
Study 23457220 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO2 target range 80‐92%
Number of subjects: 16
Study 23457220 — intervention group
Group type: COMPARATOR
Intervention: SpO2 target range 85‐96%
Number of subjects: 16
Study 20817750 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized imagery induction (stress)
Number of subjects: 37
Study 20817750 — intervention group
Group type: COMPARATOR
Intervention: Personalized imagery induction (neutral)
Number of subjects: 37
Study 20817750 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 37
Study 19298496 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 984
Study 19298496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 16421131 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring (n = 69, simple tablet count and electronic monitoring)
Number of subjects: 112
Study 16421131 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 43, no monitoring)
Number of subjects: 112
Study 16421131 — intervention group
Group type: EXPERIMENTAL
Intervention: Self report
Number of subjects: 112
Study 16421131 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 112
Study 16421131 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple tablet count
Number of subjects: 112
Study 14738230 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (2x250 mg x day(‐1))
Number of subjects: 30
Study 14738230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (2x250 mg x day(‐1))
Number of subjects: 30
Study 14738230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11389294 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture (Heliox)
Number of subjects: 29
Study 11389294 — intervention group
Group type: COMPARATOR
Intervention: Racemic epinephrine (RE)
Number of subjects: 29
Study 8996307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (1 mg/kg body weight)
Number of subjects: 12
Study 8996307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8097802 — intervention group
Group type: EXPERIMENTAL
Intervention: oral captopril (n = 8)
Number of subjects: 16
Study 8097802 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 8)
Number of subjects: 16
Study 3316564 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and ampicillin
Number of subjects: 0
Study 3316564 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin
Number of subjects: 0
Study 31520460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblopasvir (30 or 60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks
Number of subjects: 110
Study 31520460 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblopasvir (60 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks (for patients with cirrhosis)
Number of subjects: 110
Study 30563215 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of vitamin D (7 drops, 1750 IU/day)
Number of subjects: 44
Study 30563215 — intervention group
Group type: COMPARATOR
Intervention: Monthly administration of vitamin D (50,000 IU/month)
Number of subjects: 44
Study 27569936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Everolimus (TAC/EVL)
Number of subjects: 30
Study 27569936 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/Enteric-Coated Mycophenolate Sodium (TAC/EC-MPS)
Number of subjects: 30
Study 24982088 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-222 (monotherapy)
Number of subjects: 0
Study 24982088 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-222 and telaprevir (dual combination therapy) for 12 weeks
Number of subjects: 0
Study 22439742 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) followed by 2 years of adjuvant hormone therapy (HT) with luteinizing hormone-releasing hormone agonist.
Number of subjects: 340
Study 22439742 — intervention group
Group type: COMPARATOR
Intervention: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) without long-term hormone therapy.
Number of subjects: 340
Study 20536522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Education Programme (group A)
Number of subjects: 256
Study 18432175 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 18432175 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 0
Study 16102379 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT1 (original version starting with three items addressing frequency and quantity of alcohol use)
Number of subjects: 10803
Study 16102379 — intervention group
Group type: COMPARATOR
Intervention: AUDIT2 (version with items addressing frequency and quantity of alcohol use at the end)
Number of subjects: 10803
Study 11828745 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid creams (Lidomex) alone
Number of subjects: 20
Study 11828745 — intervention group
Group type: EXPERIMENTAL
Intervention: Admixture of Lidomex ointment and urea/heparinoid ointments
Number of subjects: 20
Study 11828745 — intervention group
Group type: COMPARATOR
Intervention: Ointments alone
Number of subjects: 20
Study 9988786 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy
Number of subjects: 116
Study 9988786 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 116
Study 7760608 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen in nitrogen during anaesthesia induction
Number of subjects: 12
Study 7760608 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen during induction and 40% oxygen in nitrogen thereafter
Number of subjects: 12
Study 7760608 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen (subgroup A)
Number of subjects: 12
Study 7760608 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (subgroup B)
Number of subjects: 12
Study 2182205 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine CO2
Number of subjects: 0
Study 2182205 — intervention group
Group type: EXPERIMENTAL
Intervention: Two per cent lidocaine
Number of subjects: 0
Study 2182205 — intervention group
Group type: EXPERIMENTAL
Intervention: Two per cent lidocaine with pH adjusted by bicarbonate
Number of subjects: 0
Study 2182205 — intervention group
Group type: EXPERIMENTAL
Intervention: All three solutions
Number of subjects: 0
Study 6111126 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (Halcion) 0.25 mg
Number of subjects: 55
Study 6111126 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (Rohypnol) 2 mg
Number of subjects: 55
Study 31709697 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based, low-energy, low-carbohydrate diet (800-1000 kcal/day, <26% energy) for 8 weeks with behavioral support
Number of subjects: 33
Study 31709697 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 33
Study 29306491 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo flash located <15 mm from the fundus
Number of subjects: 230
Study 29306491 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo flash located >15 mm from the fundus
Number of subjects: 230
Study 29306491 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo flash movement/migration at 60 minutes after ET
Number of subjects: 230
Study 29306491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundal position of embryo flash
Number of subjects: 230
Study 29306491 — intervention group
Group type: EXPERIMENTAL
Intervention: Static position of embryo flash
Number of subjects: 230
Study 29306491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical position of embryo flash
Number of subjects: 230
Study 27546774 — intervention group
Group type: COMPARATOR
Intervention: Critical care outreach delivered by a team of intensive care nurses implemented across general hospital wards.
Number of subjects: 18682
Study 25081360 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 286
Study 25081360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 286
Study 25081360 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 286
Study 22915639 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gp120 vaccination
Number of subjects: 1725
Study 22915639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1725
Study 21081600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewer's signed report made available on the BMJ's website alongside the published paper (intervention group)
Number of subjects: 471
Study 21081600 — intervention group
Group type: COMPARATOR
Intervention: BMJ's normal procedure (control group)
Number of subjects: 471
Study 18757088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (5 mg, with intention to increase to 7.5 mg twice a day)
Number of subjects: 10917
Study 18757088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917
Study 18757088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study 15750103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once daily for a mean duration of 27 days (SD 12.2 days)
Number of subjects: 76
Study 15750103 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for a mean duration of 27 days (SD 13.9 days)
Number of subjects: 76
Study 15750103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and Placebo
Number of subjects: 76
Study 12651918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site B
Number of subjects: 8
Study 12651918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site C
Number of subjects: 8
Study 12651918 — intervention group
Group type: COMPARATOR
Intervention: Control site (Site A)
Number of subjects: 8
Study 12651918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Sites B and C
Number of subjects: 8
Study 10961763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (10% solution, 1 ml, 40-50 mg per application)
Number of subjects: 15
Study 10961763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (10% solution, 1 ml)
Number of subjects: 15
Study 10961763 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study 8856622 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 21
Study 8856622 — intervention group
Group type: COMPARATOR
Intervention: paracetamol
Number of subjects: 21
Study 1630740 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 0
Study 6377866 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) alone
Number of subjects: 207
Study 6377866 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) + hydroxyurea (HU)
Number of subjects: 207
Study 6377866 — intervention group
Group type: EXPERIMENTAL
Intervention: Semustine (SE) + dacarbazine (DA)
Number of subjects: 207
Study 6377866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) + hydroxyurea (HU) alternating with semustine (SE) + dacarbazine (DA)
Number of subjects: 207
Study 6377866 — intervention group
Group type: EXPERIMENTAL
Intervention: Semustine (SE) + razoxane (RA)
Number of subjects: 207
Study 6377866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin (MI) + dacarbazine (DA)
Number of subjects: 207
Study 31775699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vlog unboxing fruit and vegetables (preparing and tasting)
Number of subjects: 350
Study 31775699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vlog doing a challenge with fruit and vegetables (e.g., contests, tricks, games)
Number of subjects: 350
Study 31775699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study 29373294 — intervention group
Group type: EXPERIMENTAL
Intervention: povidone-iodine
Number of subjects: 126
Study 29373294 — intervention group
Group type: EXPERIMENTAL
Intervention: povidone-iodine with a drape
Number of subjects: 126
Study 29373294 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorhexidine-alcohol
Number of subjects: 126
Study 29373294 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorhexidine-alcohol with a drape
Number of subjects: 126
Study 26618547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1108
Study 26253734 — intervention group
Group type: COMPARATOR
Intervention: Lead shield
Number of subjects: 230
Study 26253734 — intervention group
Group type: COMPARATOR
Intervention: Surgical cap
Number of subjects: 230
Study 22683252 — intervention group
Group type: EXPERIMENTAL
Intervention: PF 1 mg + ranibizumab (combination) Q4W
Number of subjects: 151
Study 22683252 — intervention group
Group type: COMPARATOR
Intervention: ranibizumab Q4W
Number of subjects: 151
Study 22683252 — intervention group
Group type: EXPERIMENTAL
Intervention: PF 1 mg every 4 weeks (Q4W)
Number of subjects: 151
Study 22683252 — intervention group
Group type: EXPERIMENTAL
Intervention: PF 3 mg Q4W
Number of subjects: 151
Study 22683252 — intervention group
Group type: EXPERIMENTAL
Intervention: PF 3 mg every 2 weeks (Q2W)
Number of subjects: 151
Study 22683252 — intervention group
Group type: EXPERIMENTAL
Intervention: PF monotherapy groups
Number of subjects: 151
Study 20236984 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based, multi-level intervention
Number of subjects: 2343
Study 20236984 — intervention group
Group type: COMPARATOR
Intervention: Standard health curriculum (Control)
Number of subjects: 2343
Study 18523642 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based intervention for caregivers, including information on dementia, guidance on behaviour management, psychiatric assessment, and psychotropic medication if needed.
Number of subjects: 81
Study 18523642 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (received intervention after 6 months)
Number of subjects: 81
Study 15777680 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin intake
Number of subjects: 1700
Study 15777680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low riboflavin, B12, B6, and folate intake
Number of subjects: 1700
Study 15777680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation
Number of subjects: 1700
Study 15777680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1700
Study 11994976 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) alone (15, 45, or 75 mg/m²/day on alternate days for 21 days)
Number of subjects: 30
Study 11994976 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (Tam) alone
Number of subjects: 30
Study 11994976 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) + Tamoxifen (Tam)
Number of subjects: 30
Study 10348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) diet
Number of subjects: 12
Study 10348498 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) diet
Number of subjects: 12
Study 10348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) diet on day 7
Number of subjects: 12
Study 10348498 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) diet on day 7
Number of subjects: 12
Study 8948338 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 Gy in 5 weeks
Number of subjects: 379
Study 8948338 — intervention group
Group type: COMPARATOR
Intervention: 59.4 Gy in 6.6 weeks
Number of subjects: 379
Study 1816813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% epinephrine-free Articain solution (Ultracain 2%)
Number of subjects: 0
Study 1816813 — intervention group
Group type: COMPARATOR
Intervention: 4% Articain solution with epinephrine (Ultracain D-S)
Number of subjects: 0
Study 6095602 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (radiosensitizer)
Number of subjects: 410
Study 6095602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 6095602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (bleomycin, methotrexate, vincristine) before irradiation
Number of subjects: 410
Study 31622159 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato purée ingestion
Number of subjects: 12
Study 31622159 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate gel ingestion
Number of subjects: 12
Study 31622159 — intervention group
Group type: COMPARATOR
Intervention: Water condition
Number of subjects: 12
Study 29893297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 16
Study 29893297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with or without pioglitazone)
Number of subjects: 16
Study 29893297 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 16
Study 27989278 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention, relaxation, physical exercise and moor applications (3-week program)
Number of subjects: 88
Study 27989278 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (WG)
Number of subjects: 88
Study 24509026 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 930
Study 19803574 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational treatment (telephone motivational interview and mailed self-help workbook)
Number of subjects: 314
Study 19803574 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational booster treatment (telephone motivational interview, workbook, and 6 booster calls over 9 months)
Number of subjects: 314
Study 19803574 — intervention group
Group type: COMPARATOR
Intervention: Workbook only control
Number of subjects: 314
Study 19803574 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief booster treatment
Number of subjects: 314
Study 15712819 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Appropriate Breast Educational Intervention Program (CABHEIP)
Number of subjects: 120
Study 15712819 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (education on poison control)
Number of subjects: 120
Study 11680565 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 105
Study 11680565 — intervention group
Group type: COMPARATOR
Intervention: Detox-only
Number of subjects: 105
Study 9414143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg)
Number of subjects: 10
Study 9414143 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (200 mg)
Number of subjects: 10
Study 9414143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7969599 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking advice (WA) given to non-professional caregivers of MHI patients, with a waking interval of 1-4 hours.
Number of subjects: 326
Study 3670868 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 200
Study 3670868 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction with suggestion
Number of subjects: 200
Study 3670868 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion
Number of subjects: 200
Study 3670868 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 30770308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 30770308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30770308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide with dose reductions
Number of subjects: 0
Study 29936419 — intervention group
Group type: EXPERIMENTAL
Intervention: Golf training (24-week, 90-120 min sessions/week)
Number of subjects: 106
Study 29936419 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 106
Study 27402596 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute administration of ghrelin
Number of subjects: 21
Study 25127084 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative yoga
Number of subjects: 171
Study 25127084 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 171
Study 22432824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary injection of piroxicam (0.4 mL)
Number of subjects: 65
Study 22432824 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (intraligamentary injection of lidocaine, 0.4 mL)
Number of subjects: 65
Study 19158153 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by female physicians
Number of subjects: 1857
Study 19158153 — intervention group
Group type: COMPARATOR
Intervention: Treatment by male physicians
Number of subjects: 1857
Study 19158153 — intervention group
Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 1857
Study 19158153 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 1857
Study 19158153 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender of physicians
Number of subjects: 1857
Study 17192771 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,4-butanediol (BD) 25 mg/kg
Number of subjects: 8
Study 17192771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15114226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine (0.5 mg/kg)
Number of subjects: 79
Study 15114226 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 79
Study 11404446 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic employees
Number of subjects: 400
Study 11404446 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic employees
Number of subjects: 400
Study 9779697 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg OTFC
Number of subjects: 62
Study 9779697 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg OTFC
Number of subjects: 62
Study 9779697 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC (dose-titrated)
Number of subjects: 62